secwatch.observer — SEC 8-K summary
======================================

Issuer:     Coherus Oncology, Inc. (CHRS)
CIK:        0001512762
Form:       8-K
Filed at:   2025-01-13T23:59:59+00:00
Accession:  0001558370-25-000167
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Coherus provides preliminary Q4/FY2024 revenue and cash; UDENYCA allocated due to strong demand
--------------------------------------------------------------------------------

- Preliminary unaudited net revenues for Q4 and FY2024 presented at J.P. Morgan Healthcare Conference.
- Cash, cash equivalents and investments as of Dec 31, 2024 disclosed; final results may materially differ.
- All three presentations of UDENYCA temporarily allocated due to strong demand in Q4 2024 and into Q1 2025.
- Financial closing procedures not yet complete; independent auditor has not reviewed these preliminary results.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1512762/000155837025000167/0001558370-25-000167-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1512762/000155837025000167/chrs-20250113x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-000167

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer